BACKGROUND: Macular ganglion cell-inner plexiform layer (mGCIPL) is an emerging biomarker of neuroaxonal degeneration in multiple sclerosis (MS). OBJECTIVE: We aimed to determine cut-off values of mGCIPL thinning for discriminating between progressing and stable patients in relapsing multiple sclerosis (RMS). METHODS: This is a 3-year prospective longitudinal study on 183 RMS patients with annual optical coherence tomography. Best possible cut-off values of baseline mGCIPL and annual loss of macular ganglion cell-inner plexiform layer (aLmGCIPL) for discriminating clinically progressing (physical progression or cognitive decline) from stable patients were defined by receiver operating characteristics analysis and tested using multivariate regression models. RESULTS: Baseline mGCIPL thickness <77 µm was associated with an increased risk (hazard ratio: 2.7, 95% confidence interval (CI): 1.5-4.7, p < 0.001) of disability progression. An aLmGCIPL cut-off ⩾1 µm accurately identified clinically progressing patients (87% sensitivity at 90% specificity) and was a strong predictor of clinical progression (odds ratio: 18.3, 95% CI: 8.8-50.3). CONCLUSION: We present evidence that cross-sectionally measured mGCIPL thickness and annualized thinning rates of mGCIPL are able to identify clinically progressing RMS with high accuracy.
BACKGROUND: Macular ganglion cell-inner plexiform layer (mGCIPL) is an emerging biomarker of neuroaxonal degeneration in multiple sclerosis (MS). OBJECTIVE: We aimed to determine cut-off values of mGCIPL thinning for discriminating between progressing and stable patients in relapsing multiple sclerosis (RMS). METHODS: This is a 3-year prospective longitudinal study on 183 RMS patients with annual optical coherence tomography. Best possible cut-off values of baseline mGCIPL and annual loss of macular ganglion cell-inner plexiform layer (aLmGCIPL) for discriminating clinically progressing (physical progression or cognitive decline) from stable patients were defined by receiver operating characteristics analysis and tested using multivariate regression models. RESULTS: Baseline mGCIPL thickness <77 µm was associated with an increased risk (hazard ratio: 2.7, 95% confidence interval (CI): 1.5-4.7, p < 0.001) of disability progression. An aLmGCIPL cut-off ⩾1 µm accurately identified clinically progressing patients (87% sensitivity at 90% specificity) and was a strong predictor of clinical progression (odds ratio: 18.3, 95% CI: 8.8-50.3). CONCLUSION: We present evidence that cross-sectionally measured mGCIPL thickness and annualized thinning rates of mGCIPL are able to identify clinically progressing RMS with high accuracy.
Authors: Natascha Schurz; Lydia Sariaslani; Patrick Altmann; Fritz Leutmezer; Christoph Mitsch; Berthold Pemp; Paulus Rommer; Tobias Zrzavy; Thomas Berger; Gabriel Bsteh Journal: Eye Brain Date: 2021-03-12
Authors: Giacomo Lus; Marco André Bassano; Vincenzo Brescia Morra; Simona Bonavita; Antonio Gallo; Davide Maimone; Laura Malerba; Giorgia Teresa Maniscalco; Francesco Saccà; Giuseppe Salemi; Renato Turrini; Salvatore Cottone; Edoardo Sessa; Maria Buccafusca; Luigi Maria Edoardo Grimaldi Journal: Neurol Sci Date: 2022-09-17 Impact factor: 3.830
Authors: Gabriel Bsteh; Harald Hegen; Patrick Altmann; Michael Auer; Klaus Berek; Franziska Di Pauli; Fritz Leutmezer; Paulus Rommer; Sebastian Wurth; Anne Zinganell; Tobias Zrzavy; Florian Deisenhammer; Thomas Berger Journal: Eur J Neurol Date: 2021-04-02 Impact factor: 6.089
Authors: Gabriel Bsteh; Harald Hegen; Patrick Altmann; Michael Auer; Klaus Berek; Franziska Di Pauli; Sebastian Wurth; Anne Zinganell; Paulus Rommer; Florian Deisenhammer; Fritz Leutmezer; Thomas Berger Journal: Mult Scler J Exp Transl Clin Date: 2020-10-29
Authors: Nik Krajnc; Patrick Altmann; Katharina Riedl; Christoph Mitsch; Thomas Berger; Fritz Leutmezer; Paulus Rommer; Berthold Pemp; Gabriel Bsteh Journal: Front Neurol Date: 2022-03-07 Impact factor: 4.003